China’s Strategic Advance in the Global Biosimilars Market: Implications for Biopharma Competition and Innovation

Trade & Industry, , , , , ,

China has transitioned from a generics and API producer to a formidable global competitor in biosimilars, securing international regulatory approvals and forming strategic partnerships that enhance its presence in key markets. This evolution signals a broader shift in China’s pharmaceutical industry towards innovation, quality, and global integration.

READ MORE

Navigating NIH Registration: A Strategic Entry Point for German Enterprises into U.S. Biomedical Research Funding

Trade & Industry, , , , , ,

The National Institutes of Health (NIH) offers substantial research funding opportunities vital for German companies and institutions aiming to engage in U.S. biomedical innovation. Registration through platforms like eRA Commons is essential for accessing these grants, fostering transatlantic collaboration, and integrating into the U.S. research ecosystem.

READ MORE